Nozin, leaders in developing and implementing MRSA / MSSA risk mitigation programs, introduces NOVASM. A proprietary suite of tools and services, NOVASM programs are guided by experienced consultants and proven to reduce infection risks while improving patient care.
Methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-sensitive Staphylococcus aureus (MSSA) infections are a major component of total healthcare-associated infections (HAIs).
Patients who are colonized with MRSA in the nares are 14 to 20 times more likely to acquire MRSA infection than non-carriers.
NOVASM colonization risk mitigation programs reduce colonization, which reduces infection risk.
Facilities that have adopted the NOVA programs approach are reporting significant outcomes such as:
reduction in MRSA bacteremia hospital-wide2
Advent Health North Pinellas, FL
reduction in total hip and knee SSI2
Wellstar Cobb Hospital, GA
decline in MRSA bacteremia2
Jackson Health System, FL
Visit nozin.com/clinical-outcomes for more data.
Nozin NOVASM programs are a proprietary suite of analytical tools and services guided by experienced consultants. Built on shared knowledge from hundreds of facility implementations, NOVASM programs are proven to reduce infection risks while improving patient care.
We know that making the change from traditional strategies can be a challenge. Here’s what you can expect when you partner with Nozin NOVASM .
More outcomes data published or presented than for any other nasal antiseptic
15-year safety record
Millions of users
Fast, easy, pleasant application – preferred by staff and patients
Patented Nozaseptin® formula:
Proprietary Popswab® delivery system
More daily decolonization outcomes data
The right tool for nasal colonization risk mitigation programs
Rechargeable for second nostril application
Facilities that have implemented Nozin NOVASM programs have shown up to $1.4 million annual cost savings2 and up to 60% reduction in PPE use2. Take the first step today.